Beginning on October 6, 2014, hydrocodone combination
products (HCPs) will be moved from Schedule III to Schedule II substances at
the recommendation of the Secretary of the Department of Health & Human
Services. This change was included in the Federal Register as part of the Drug Enforcement Agency’s
recent publication of its final rule on the matter. Read here
for important need-to-know information on what this change means for family
physicians and their patients.
No comments:
Post a Comment